Paclitaxel, Carboplatin, Ipilimumab, and Nivolumab Treatment Protocol for Lung Cancer

Paclitaxel + carboplatin + ipilimumab + nivolumab is one of the combined immunochemotherapy protocols generally used for non-small cell lung cancer (NSCLC). It is used particularly in patients with metastatic or advanced NSCLC.

P = Paclitaxel
C = Carboplatin
IP = Ipilimumab
NI = Nivolumab

Paclitaxel: Binds to microtubules and prevents their disassembly. It halts cell division (mitosis), causing cell death. As a result, actively proliferating tumor cells are killed, rapidly reducing tumor burden.

Carboplatin: Causes DNA crosslinking, preventing DNA replication and repair and leading to cell death (apoptosis). As a result, it damages tumor cell genetic material and prevents division. It has a synergistic effect, particularly with paclitaxel.

Nivolumab (anti-PD-1): Tumor cells display a protein called PD-L1 on their surface to evade the immune system. This protein binds to the PD-1 receptor on T cells, leaving them “asleep.” Nivolumab blocks the PD-1 receptor and reactivates T cells, allowing them to recognize and destroy tumor cells again.

Ipilimumab (anti-CTLA-4): CTLA-4, involved in early T-cell activation, is a negative regulator: a braking mechanism. Ipilimumab blocks this inhibitory signal. T-cell activation increases, strengthening the immune response. Together with nivolumab, it produces a broader, deeper immune response.

Goals of Treatment

• Rapidly reduce tumor burden: Chemotherapy (paclitaxel + carboplatin) rapidly kills tumor cells and helps bring the disease under control. The aim is to shrink large or widespread tumor masses quickly.
• Activate the immune system for long-term tumor control: Nivolumab and ipilimumab stimulate the body's immune system to recognize and destroy tumor cells. This can produce long-term disease control or even a durable response in some patients.
• Improve treatment success by combining chemotherapy and immunotherapy: Chemotherapy reduces suppression of the immune system, allowing immunotherapy to work more effectively. Immunotherapy creates a lasting defense against tumor cells remaining after chemotherapy.
• Extend life and improve quality of life: Studies, such as CheckMate 9LA, have shown that this combination prolongs survival and reduces symptoms in some patients.
• Provide a strong and effective first-line treatment:  Starting treatment intensively at an early stage helps prevent the development of resistant tumor clones later.

Treatment Indication

• Advanced (metastatic) non-small cell lung cancer (NSCLC),
• particularly squamous or non-squamous histology,
• regardless of PD-L1 level.
• Mutations such as BRAF, EGFR, and ALK must be absent.
• The ECOG performance score should be 0–2 (the patient should generally be able to carry out daily activities).
• Liver and kidney function should be adequate.
• Hematologic parameters should be suitable for treatment.
• Treatment may begin if there are no brain metastases or if they are stable/asymptomatic.
• There should be no history of autoimmune disease or immunosuppressive treatment. Conditions such as active lupus, rheumatoid arthritis, or IBD require careful assessment.

Conditions That Make Treatment Unsuitable

• Recurrence following adjuvant durvalumab or atezolizumab within the past 6 months
• Recurrence following adjuvant platinum-based chemotherapy within the past 12 months
• Previous treatment with nivolumab + ipilimumab
• Active or serious autoimmune diseases
• Conditions requiring systemic corticosteroids or immunosuppressive treatment 

SGK Reimbursement Status

• In Turkey, paclitaxel + carboplatin + nivolumab + ipilimumab combination treatment is not routinely reimbursed by the Social Security Institution (SGK) for advanced non-small cell lung cancer (NSCLC).
• The nivolumab + ipilimumab combination is not reimbursed by SGK.
• Carboplatin and paclitaxel are standard treatment medicines and are reimbursed.

Dosage

Chemotherapy 

• Paclitaxel: 175 mg/m² IV every 3 weeks
• Carboplatin: AUC 5-6 IV every 3 weeks
• Total: Usually 2 cycles.

Immunotherapy 

• Nivolumab (anti-PD-1): 360 mg IV every 3 weeks (with chemotherapy)
• Ipilimumab (anti-CTLA-4): 1 mg/kg IV every 6 weeks
• Maintenance Treatment: After chemotherapy is completed, nivolumab + ipilimumab are continued.

/p>

• On day 1, all four medicines are given intravenously:
• Nivolumab is given first. Infusion takes approximately 30 minutes.
• Ipilimumab is given second. Infusion takes approximately 30 minutes.
• Paclitaxel is given next. Infusion takes approximately 3 hours (180 minutes).
• Before paclitaxel, certain medicines will also be given intravenously to prevent allergic reactions.
• Carboplatin is given last. Infusion takes approximately 30 minutes.

Conditions Requiring Attention in This Protocol

Immune-mediated toxicities:

• While nivolumab and ipilimumab enhance the immune system, they may also cause it to attack the body's own tissues.
• Skin rash and itching, diarrhea and colitis, hepatitis (elevated AST/ALT), thyroid dysfunction, pneumonitis, muscle weakness, or neurological symptoms may occur.
• These adverse effects should be recognized early and controlled with corticosteroid treatment (such as prednisolone).

Chemotherapy-related toxicities:

• Paclitaxel can cause peripheral neuropathy, such as numbness and tingling in the hands and feet, particularly by damaging nerve endings.
• Carboplatin and paclitaxel can suppress bone marrow and cause a low white blood cell count (neutropenia), increasing the risk of infection.
• Nausea, vomiting, loss of appetite, and hair loss are common.
• Weakness and fatigue may be effects shared by chemotherapy and immunotherapy.

The combination's toxicity burden:

• This combination may cause adverse effects more frequently than immunotherapy or chemotherapy alone.
• Older patients, those with comorbidities, and patients in poor general health are at greater risk.
• Dose reduction or temporary treatment interruption may therefore be needed.

Conditions Requiring Emergency Intervention:

• Febrile neutropenia (infection and fever during a period of reduced immune defenses)
• Severe, persistent diarrhea (may be grade 3-4 colitis)
• Severe shortness of breath or dry cough (may indicate pneumonitis)
• A sudden rise in liver enzymes (hepatotoxicity)
• Neurological symptoms such as confusion or muscle weakness
• In these situations, treatment should be stopped immediately, corticosteroids started, and the patient referred to a specialist center.

Regular Monitoring and Precautions:

• Blood counts and liver and kidney function tests should be performed before each treatment cycle.
• Thyroid function (TSH and FT4) should be checked regularly.
• Patients should be asked about symptoms such as cough and shortness of breath to assess pulmonary toxicity, with imaging performed when needed.
• Patients should be informed about possible adverse effects throughout treatment and asked to report any new symptoms without delay.

Side Effects

These percentages were compiled from various clinical studies, particularly CheckMate-9LA, and real-world data. They may vary between patients.

• Fatigue: 40–60%
• Nausea: 30–50%
• Loss of appetite (anorexia): 20–40%
• Rash (skin redness, itching): 20–35%
• Diarrhea: 20–30%
• Hair loss (alopecia): 20–30%
• Shortness of breath (dyspnea): 15–25%
• Fever: 10–20%
• Elevated liver enzymes (AST/ALT): 10–20%
• Thyroid disorders (hypothyroidism or hyperthyroidism): 10–15%
• Peripheral neuropathy (numbness or tingling in the hands/feet): 10–15%
• Cough: 10–15%
• Vomiting: 10–15%
• Hyponatremia (low sodium): around 10%
• Anemia (low red blood cell count): around 10%
• Pneumonitis (immune-mediated lung inflammation): 5–10%
• Colitis (intestinal inflammation): 5–10%
• Neutropenia (low white blood cell count): 5–10%
• Serious hepatitis (immune-mediated liver inflammation): 1–5%
• Endocrinopathy (hypophysitis, etc.): 1–3%
• Neurological adverse effects (muscle weakness, headache, impaired balance): <1–3%